DelveInsight, a leading market research and business consulting firm specializing in life sciences, has published its latest report, “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034.” The report provides a comprehensive assessment of the Type 1 Diabetes Market Size, Type 1 Diabetes Epidemiology, current treatment landscape, Type 1 Diabetes Pipeline, emerging therapies, competitive intelligence, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan (7MM).
Keen to know how the Type 1 Diabetes Market will evolve by 2034? Request our sample page athttps://www.delveinsight.com/sample-request/type-1-diabetes-market
Key Takeaways from the Type 1 Diabetes Market
The Type 1 Diabetes Market Size across the seven major markets (7MM) is expected to witness significant growth during the forecast period (2025–2034), driven by increasing disease prevalence, expanding treatment options, and rapid advances in regenerative medicine and cell-based therapies.
According to DelveInsight’s analysis, the Type 1 Diabetes Market is projected to increase from an indicative market value of 10 in 2020 to 16 by 2034, supported by increasing adoption of innovative therapies and improved disease management strategies.
The United States accounted for the largest Type 1 Diabetes Market among the seven major markets owing to its large patient population, favorable reimbursement landscape, and rapid adoption of novel therapies.
According to the National Institutes of Health (NIH), more than 1.4 million people in the United States are living with Type 1 Diabetes, including approximately 80,000 patients with brittle Type 1 Diabetes, a severe form of the disease associated with recurrent hypoglycemia and increased risk of complications.
As per the CDC (2024), nearly 304,000 children and adolescents in the United States are living with Type 1 Diabetes, while approximately 1.7 million adults report having T1D and using insulin therapy.
According to the Japan Preventive Association of Lifestyle-related Disease, an estimated 139,000 individuals in Japan were living with Type 1 Diabetes in 2020.
According to the World Health Organization (WHO), approximately 9 million people worldwide were living with Type 1 Diabetes in 2017, with the majority residing in high-income countries.
The current treatment landscape includes approved therapies such as LANTIDRA (CellTrans) and TZIELD (Sanofi), while several emerging therapies—including Zimislecel, LADARIXIN, OZTx-410, PEC-Encap (VC-01), and ProTrans-3—are expected to reshape the future Type 1 Diabetes Treatment Market.
Key Factors Driving the Type 1 Diabetes Market
Rising Prevalence of Type 1 Diabetes
The growing global prevalence of Type 1 Diabetes among both pediatric and adult populations continues to increase the diagnosed patient pool across the seven major markets. Improved awareness, earlier diagnosis, and enhanced access to healthcare services are contributing to increased treatment uptake and market expansion.
Advancements in Cell and Regenerative Therapies
The development of stem cell-derived islet replacement therapies, regenerative medicine, and immune-modulating treatments is transforming the future of the Type 1 Diabetes Pipeline. These innovative therapies aim to restore endogenous insulin production and address the underlying cause of the disease rather than simply managing blood glucose levels.
Increasing Adoption of Advanced Diabetes Therapies
The growing use of continuous glucose monitoring systems, insulin pumps, long-acting insulin analogs, and disease-modifying therapies is improving glycemic control and patient outcomes. Regulatory approvals of novel therapies such as LANTIDRA and TZIELD, along with the anticipated launch of multiple late-stage pipeline candidates, are expected to accelerate the growth of the Type 1 Diabetes Market throughout the forecast period.
Type 1 Diabetes Competitive Landscape
The Type 1 Diabetes Market is undergoing a significant transformation as pharmaceutical and biotechnology companies increasingly focus on disease-modifying therapies, regenerative medicine, and cell-based approaches that go beyond conventional insulin replacement. While intensive insulin therapy remains the standard of care, the emergence of stem cell-derived islet replacement therapies, immunotherapies, and regenerative treatments is expected to redefine the future Type 1 Diabetes Treatment Market.
The current treatment landscape includes approved therapies such as LANTIDRA (CellTrans), the first FDA-approved allogeneic pancreatic islet cell therapy for adults with brittle Type 1 Diabetes, and TZIELD (teplizumab), the first therapy approved to delay the onset of Stage 3 Type 1 Diabetes in at-risk individuals. These therapies represent important milestones in shifting treatment from symptom management toward disease modification.
The Type 1 Diabetes Pipeline continues to expand with several promising late-stage candidates, including Zimislecel (Vertex Pharmaceuticals), LADARIXIN (Dompe Farmaceutici), OZTx-410 (Orizuru Therapeutics), PEC-Encap (VC-01), ProTrans-3 (NextCell Pharma), and other innovative regenerative therapies that are expected to improve long-term insulin independence and disease management.
Discover more about therapies expected to transform the Type 1 Diabetes Treatment Market and gain significant market share @ Type 1 Diabetes Treatment Landscape
Recent Developments in the Type 1 Diabetes Market
In June 2025, Vertex Pharmaceuticals announced encouraging clinical results for Zimislecel during the 85th Scientific Sessions of the American Diabetes Association, further strengthening its position as one of the most promising investigational cell therapies for Type 1 Diabetes.
In April 2025, Orizuru Therapeutics reported the successful first implantation of OZTx-410 in a patient with Type 1 Diabetes as part of an investigator-initiated clinical trial, representing a major milestone for regenerative medicine in diabetes treatment.
Vertex Pharmaceuticals expects to complete enrollment and dosing for the Phase III Zimislecel clinical trial in early 2025, with global regulatory submissions planned for 2026. The therapy has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and PRIME designations from regulatory agencies.
In October 2024, Orizuru Therapeutics initiated an investigator-sponsored clinical trial evaluating iPSC-derived islet cell sheets (OZTx-410), supporting the advancement of regenerative therapies designed to restore endogenous insulin production in patients with severe Type 1 Diabetes.
What is Type 1 Diabetes?
Type 1 Diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells, resulting in an absolute deficiency of insulin. Without sufficient insulin, glucose cannot effectively enter body cells and accumulates in the bloodstream, leading to persistent hyperglycemia and increasing the risk of severe acute and long-term complications.
Patients with Type 1 Diabetes require lifelong insulin replacement therapy through multiple daily injections or continuous insulin infusion using insulin pumps. Despite substantial advances in insulin formulations and glucose monitoring technologies, there remains no definitive cure for the disease. Emerging cell-based therapies, regenerative medicine, and immune-modulating treatments aim to restore insulin-producing cells and address the underlying autoimmune process, offering the potential for long-term disease modification.
Type 1 Diabetes Epidemiology Segmentation
The Type 1 Diabetes Epidemiology section provides historical and forecasted patient population insights across the seven major markets during the study period 2020–2034. The report analyzes:
Total Diagnosed Prevalent Cases of Type 1 Diabetes
Total Diagnosed Prevalent Cases of Brittle Type 1 Diabetes
Age-specific Diagnosed Prevalent Cases of Type 1 Diabetes
Gender-specific Diagnosed Prevalent Cases of Type 1 Diabetes
Total Diagnosed Treated Cases of Type 1 Diabetes
Scope of the Type 1 Diabetes Market Report
Therapeutic Assessment: Current and Emerging Type 1 Diabetes Therapies
Type 1 Diabetes Market Dynamics: Market Forecast, Key Assumptions, Emerging Drugs, and Future Market Outlook
Key Companies: Vertex Pharmaceuticals, Dompe Farmaceutici, Orizuru Therapeutics, ViaCyte/CRISPR Therapeutics, NextCell Pharma, CellTrans, Sanofi, and others
Key Therapies: Zimislecel, LADARIXIN, OZTx-410, PEC-Encap (VC-01), ProTrans-3, LANTIDRA, TZIELD, and others
Competitive Intelligence: SWOT Analysis, Conjoint Analysis, Pricing Trends, Market Access, and Reimbursement Assessment
Unmet Needs, KOL Perspectives, Analyst Views, and Future Market Opportunities
To know more about companies developing innovative Type 1 Diabetes therapies, visit @ Type 1 Diabetes Companies and Clinical Trials
Table of Contents
Type 1 Diabetes Market Report Introduction
Executive Summary of Type 1 Diabetes
SWOT Analysis of Type 1 Diabetes
Type 1 Diabetes Patient Share (%) Overview at a Glance
Type 1 Diabetes Market Overview at a Glance
Type 1 Diabetes Disease Background and Overview
Type 1 Diabetes Epidemiology and Patient Population
Country-specific Patient Population of Type 1 Diabetes
Current Treatment Landscape and Medical Practices
Type 1 Diabetes Unmet Needs
Emerging Therapies for Type 1 Diabetes
Type 1 Diabetes Market Outlook
Country-wise Type 1 Diabetes Market Analysis (2020–2034)
Market Access and Reimbursement
Type 1 Diabetes Market Drivers
Type 1 Diabetes Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
